The diagnosis and management of acute and chronic urticaria: 2014 update
The diagnosis and management of acute and chronic urticaria: 2014 update
复制标题
DOI：
10.1016/j.jaci.2014.02.036
复制
发表时间：
2014-05-01
影响因子：
14.2
通讯作者：
Wallace, Dana
中科院分区：
文献类型：
--
作者：
Bernstein, Jonathan A.;Lang, David M.;Wallace, Dana
这些参数由实践参数联合工作组（JTFPP）开发，代表美国过敏、哮喘和免疫学学会（AAAAI）;美国过敏、哮喘和免疫学学会（ACAAI）;以及过敏、哮喘和免疫学联合理事会。AAAAI和ACAAI共同承担了建立“急性和慢性荨麻疹的诊断和管理：2014年更新”的责任。“这是一份完整而全面的文件。医疗环境是一个不断变化的环境，并非所有建议都适用于所有患者。由于本文件包含了许多参与者的努力，没有任何一个人，包括那些在JTFPP工作的人，被授权提供这些实践参数的官方AAAAI或ACAAI解释。任何有关AAAAI或ACAAI对这些实践参数的信息或解释的请求，应直接向AAAAI、ACAAI和过敏、哮喘和免疫学联合理事会的执行办公室提出。JTFPP理解，诊断测试和治疗药物的成本是一个重要的问题，可能会适当影响特定患者的检查和治疗选择。JTFPP认识到，我们关于药物的主要建议的重点可能会有所不同，例如，取决于第三方付款人问题和产品专利到期日期。然而，由于一个给定的测试或代理的成本是如此广泛的变化，并有一个药物经济学数据的匮乏，JTFPP一般不考虑成本时，制定实践参数的建议。在特殊情况下，当药物经济学数据支持干预的成本/效益比过高时，可能会提供评论。这些参数不是为制药公司在药物推广中使用而设计的。JTFPP致力于确保实践参数基于最佳科学证据，不存在商业偏见。为此，参数制定过程包括多层严格审查。这些层包括召集起草参数的专家组、工作组评审员和每个赞助协会成员的同行评审。尽管工作组对提交出版的文件的内容负有最终责任，但将讨论每个评审员的意见，评审员将在适当时收到对意见的书面答复。为了保持潜在利益冲突的最大透明度，JTFPP和实践参数工作组的所有成员将填写一份标准的潜在利益冲突披露表，这些文件将可供赞助组织和任何其他感兴趣的个人进行外部审查。此外，在确认工作组主席人选之前，联合工作队将讨论并解决与这一选择有关的所有相关潜在利益冲突。最后，将向参数工作组的所有成员提供一份书面声明，说明确保参数开发过程无商业偏倚的重要性。
These parameters were developed by the Joint Task Force on Practice Parameters (JTFPP), representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma & Immunology. The AAAAI and ACAAI have jointly accepted responsibility for establishing "The diagnosis and management of acute and chronic urticaria: 2014 update.'' This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the JTFPP, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology.The JTFPP understands that the cost of diagnostic tests and therapeutic agents is an important concern that might appropriately influence the work-up and treatment chosen for a given patient. The JTFPP recognizes that the emphasis of our primary recommendations regarding a medication might vary, for example, depending on third-party payer issues and product patent expiration dates. However, because a given test or agent's cost is so widely variable and there is a paucity of pharmacoeconomic data, the JTFPP generally does not consider cost when formulating practice parameter recommendations. In extraordinary circumstances, when the cost/benefit ratio of an intervention is prohibitive, as supported by pharmacoeconomic data, commentary might be provided. These parameters are not designed for use by pharmaceutical companies in drug promotion.The JTFPP is committed to ensuring that the practice parameters are based on the best scientific evidence that is free of commercial bias. To this end, the parameter development process includes multiple layers of rigorous review. These layers include the workgroup convened to draft the parameter, the task force reviewers, and peer review by members of each sponsoring society. Although the task force has the final responsibility for the content of the documents submitted for publication, each reviewer comment will be discussed, and reviewers will receive written responses to comments, when appropriate.To preserve the greatest transparency regarding potential conflicts of interest, all members of the JTFPP and the practice parameter workgroups will complete a standard potential conflict of interest disclosure form, which will be available for external review by the sponsoring organization and any other interested individual. In addition, before confirming the selection of a Work Group chairperson, the Joint Task Force will discuss and resolve all relevant potential conflicts of interest associated with this selection. Finally, all members of parameter workgroups will be provided a written statement regarding the importance of ensuring that the parameter development process is free of commercial bias.